What do You Think of CPhI? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

What do You Think of CPhI?


CPhI 2012 will draw to a close later today in Madrid. the PharmTech team hope you had a successful show!

Throughout the week, we have been asking what you thought of this year's event. Here is a quick selection are some of the comments we received:

"Very busy show, but very successful and lovely warm weather."

"Crowded, but that's to be expected. Very spread out but meetings have been a success."

"Good foot fall at our stand and great response to our products. The invstment has paid off."

"My first CPhI; very overwhelming and much busier than I expected!"

"It's been successful, as usual for our company, but I'm looking forward to going home."

You can keep up to date with any last minute news and announcements via our Twitter feed @PharmTechGroup.

Or take a look at our archive of CPhI news and announcmenets here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here